618 related articles for article (PubMed ID: 20088658)
1. A review of transdermal nonpatch estrogen therapy for the management of menopausal symptoms.
Carroll N
J Womens Health (Larchmt); 2010 Jan; 19(1):47-55. PubMed ID: 20088658
[TBL] [Abstract][Full Text] [Related]
2. Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen.
Simon JA; Snabes MC
Expert Opin Investig Drugs; 2007 Dec; 16(12):2005-20. PubMed ID: 18042008
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle delivery for transdermal HRT.
Valenzuela P; Simon JA
Nanomedicine; 2012 Sep; 8 Suppl 1():S83-9. PubMed ID: 22640909
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).
Cintron D; Lahr BD; Bailey KR; Santoro N; Lloyd R; Manson JE; Neal-Perry G; Pal L; Taylor HS; Wharton W; Naftolin F; Harman SM; Miller VM
Menopause; 2018 Feb; 25(2):145-153. PubMed ID: 28832429
[TBL] [Abstract][Full Text] [Related]
5. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK
Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
[TBL] [Abstract][Full Text] [Related]
6. Transdermal hormone therapy and the risk of stroke and venous thrombosis.
Speroff L
Climacteric; 2010 Oct; 13(5):429-32. PubMed ID: 20670199
[TBL] [Abstract][Full Text] [Related]
7. Menopause, HRT and menopausal symptoms.
Kenemans P
J Epidemiol Biostat; 1999; 4(3):141-6; discussion 146-53. PubMed ID: 10695956
[TBL] [Abstract][Full Text] [Related]
8. Hormone therapy in menopause: An update on cardiovascular disease considerations.
Hale GE; Shufelt CL
Trends Cardiovasc Med; 2015 Aug; 25(6):540-9. PubMed ID: 26270318
[TBL] [Abstract][Full Text] [Related]
9. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review.
Utian WH
Health Qual Life Outcomes; 2005 Aug; 3():47. PubMed ID: 16083502
[TBL] [Abstract][Full Text] [Related]
10. Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints.
Balfour JA; Heel RC
Drugs; 1990 Oct; 40(4):561-82. PubMed ID: 2083514
[TBL] [Abstract][Full Text] [Related]
11. Comparison of steady state development and reduction of menopausal symptoms after oral or transdermal delivery of 17-β-estradiol in young healthy symptomatic menopausal women.
Rohr UD; Volko CD; Schindler AE
Horm Mol Biol Clin Investig; 2014 Jun; 18(3):123-36. PubMed ID: 25390008
[TBL] [Abstract][Full Text] [Related]
12. Oestrogen replacement in postmenopausal women.
Sassarini J; Lumsden MA
Age Ageing; 2015 Jul; 44(4):551-8. PubMed ID: 26070875
[TBL] [Abstract][Full Text] [Related]
13. Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy.
Tuomikoski P; Haapalahti P; Sarna S; Ylikorkala O; Mikkola TS
Ann Med; 2010 Jul; 42(5):334-43. PubMed ID: 20429800
[TBL] [Abstract][Full Text] [Related]
14. Ultra-low dose - new approaches in menopausal hormone therapy.
Stute P; Becker HG; Bitzer J; Chatsiproios D; Luzuy F; von Wolff M; Wunder D; Birkhäuser M
Climacteric; 2015 Apr; 18(2):182-6. PubMed ID: 25335192
[TBL] [Abstract][Full Text] [Related]
15. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages.
Deecher DC; Dorries K
Arch Womens Ment Health; 2007; 10(6):247-57. PubMed ID: 18074100
[TBL] [Abstract][Full Text] [Related]
16. Vasomotor symptoms in menopause: where we've been and where we're going.
Pinkerton JV; Zion AS
J Womens Health (Larchmt); 2006 Mar; 15(2):135-45. PubMed ID: 16536677
[TBL] [Abstract][Full Text] [Related]
17. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
18. Low use of effective and safe therapies for moderate to severe menopausal symptoms: a cross-sectional community study of Australian women.
Worsley R; Bell RJ; Gartoulla P; Davis SR
Menopause; 2016 Jan; 23(1):11-7. PubMed ID: 26240945
[TBL] [Abstract][Full Text] [Related]
19. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
[TBL] [Abstract][Full Text] [Related]
20. Treating vasomotor symptoms of menopause: the nurse practitioner's perspective.
Alexander IM; Moore A
J Am Acad Nurse Pract; 2007 Mar; 19(3):152-63. PubMed ID: 17341283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
